Related references
Note: Only part of the references are listed.Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia
Mark A. Deeg et al.
DIABETES CARE (2007)
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus - A meta-analysis of randomized trials
A. Michael Lincoff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Long-term risk of cardiovascular events with rosiglitazone - A meta-analysis
Sonal Singh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study
Bernard Chappuis et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction - Results from the PROactive (PROactive 05) study
Erland Erdmann et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome
PO Szapary et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Low-density lipoprotein size and cardiovascular risk assessment
M Rizzo et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2006)
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
RB Goldberg et al.
DIABETES CARE (2005)
Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2 - Results of a pilot study
KG Parhofer et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2005)
Lipids and lipoproteins in patients with type 2 diabetes
RM Krauss
DIABETES CARE (2004)
A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors
E Chiquette et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension -: A double-blind, placebo-controlled study
K Winkler et al.
DIABETES CARE (2003)
Diabetic dyslipidaemia: from basic research to clinical practice
MR Taskinen
DIABETOLOGIA (2003)
Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes
FJ Gomez-Perez et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2002)
Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes - A 6-month randomized placebo-controlled dose-response study
S Aronoff et al.
DIABETES CARE (2000)
Share Paper
